Eiger biopharmaceuticals, inc. (EIGR)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Operating expenses:
Research and development

48,404

51,791

51,874

51,011

44,447

37,091

32,859

25,808

27,567

29,519

31,117

33,044

35,633

33,014

27,261

21,299

12,587

8,117

-10,378

-7,172

-4,199

644

4,234

3,489

2,725

426

0

0

0

General and administrative

18,297

17,113

16,611

16,007

15,019

13,956

12,680

11,764

11,473

12,001

12,727

13,264

12,795

13,106

12,661

10,159

8,259

4,855

-3,905

-1,852

-405

872

4,791

2,928

1,679

526

0

0

0

Total operating expenses

66,701

68,904

68,485

67,018

59,466

51,047

45,539

37,572

39,040

41,520

43,844

46,308

48,428

46,120

39,922

31,458

20,846

12,972

-14,283

-9,024

-4,604

1,516

9,025

6,417

4,404

952

0

0

0

Loss from operations

-66,701

-68,904

-68,485

-67,018

-59,466

-51,047

-45,539

-37,572

-39,040

-41,520

-43,844

-46,308

-48,428

-46,120

-39,922

-31,458

-20,846

-12,972

14,283

9,024

4,604

-1,516

-9,025

-6,417

-4,404

-952

0

0

0

Interest expense

3,525

3,406

3,273

3,070

2,696

2,329

1,969

1,676

1,559

1,524

1,134

746

368

690

0

0

0

-

-

-

-

-

0

0

0

-

-

-

-

Interest income

1,929

2,073

1,941

1,727

1,414

997

743

470

394

410

0

0

0

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Other income (expense), net

-

-15

-16

0

-1

-12

-24

167

0

-

0

0

-

-374

0

0

0

-

-

-

-

-

0

0

0

-

0

0

0

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Consolidated net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Net loss attributable to non-controlling interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net loss

-68,302

-70,252

-69,833

-68,361

-60,749

-52,391

-46,783

-38,809

-40,040

-42,448

-44,323

-46,523

-48,578

-47,087

0

0

0

-

-

-

-

-

0

0

-

-

0

0

0

Change in fair value of non-controlling interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Consolidated net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Unrealized (loss) gain on investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

Net loss and comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

-

-

-

-

-

Comprehensive loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

0

Net loss per common share, basic and diluted

-0.62

-0.67

-0.76

-0.75

-0.90

-0.98

-1.20

-0.82

-0.84

-1.09

-1.10

-1.33

-1.34

5.94

-1.49

-1.87

-10.42

-30.00

-14.70

-13.34

-4.15

-6.44

-0.40

-0.38

-0.60

14.22

-6.17

-8.98

-3.99

Weighted-average common shares outstanding, basic and diluted

24,501

24,127

24,437

23,408

19,168

17,706

14,255

12,045

10,529

9,811

8,372

8,367

8,360

8,400

7,622

7,069

935

273

195

193

193

-50,429

20,752

18,511

11,939

-1,877

884

884

884